Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 9/20 | 0.33 |
| ▸ | MPG | P29372 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 5/20 | 0.32 |
| ▸ | MGAM | O43451 | 2/20 | 0.32 |
| ▸ | AGL | P35573 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LCT | P09848 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23930930 | 1.00 | GBA1 (0.33) | GBA1MPGGAAMGAMAGL | |
| SCHEMBL2908778 | 0.86 | POLB (0.32) | — | |
| SCHEMBL2908775 | 0.86 | POLB (0.32) | — | |
| SCHEMBL3372261 | 0.86 | POLB (0.32) | — | |
| SCHEMBL9928687 | 0.83 | CHRNB2 (0.31) | GAA | |
| SCHEMBL6127398 | 0.83 | CHRNB2 (0.31) | GAA | |
| SCHEMBL6127402 | 0.83 | CHRNB2 (0.31) | GAA | |
| SCHEMBL3025369 | 0.82 | CYP46A1 (0.34) | GBA1GAA | |
| SCHEMBL15718081 | 0.82 | GBA1 (0.32) | GBA1GAA | |
| SCHEMBL3025364 | 0.82 | CYP46A1 (0.34) | GBA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186575-B2 | Treatment of helicobacter pylori infections | Alber Einslein College of Medicine (US) | 2021-11-30 | — | — | US | disclosed |
| US-20150210701-A1 | TREATMENT OF HELICOBACTER PYLORI INFECTIONS | ALBERTEINSTIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2015-07-30 | — | — | US | disclosed |
| WO-2014025842-A1 | TREATMENT OF HELICOBACTER PYLORI INFECTIONS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2014-02-13 | — | — | WO | disclosed |
| US-20090325986-A1 | Deazapurine Analogs of 1'-Aza-L-Nucleosides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210701-A1 | TREATMENT OF HELICOBACTER PYLORI INFECTIONS | MTAP, TPMT, UNG | GBA1 1297/4885MPG 6/4885GAA 185/4885 |
| US-11186575-B2 | Treatment of helicobacter pylori infections | MTAP, UNG, TPMT | GBA1 1081/4885MPG 8/4885GAA 125/4885 |
| US-20090325986-A1 | Deazapurine Analogs of 1'-Aza-L-Nucleosides | TPMT, TYMP, DUT | GBA1 707/4885MPG 77/4885GAA 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.